Monoclonal antibody 'nirsevimab' highly effective in preventing severe RSV in infants, reducing hospitalisations and ICU ...

Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis published in The ...

The plans amount to an extraordinary flex of Robert F. Kennedy Jr.’s power as health secretary to make decisions ordinarily ...

HHS and the National Institutes of Health are developing a project that involves producing vaccines from chemically inactivated whole viruses with the goal of making “universal” vaccines that protect ...

VashonBePrepared has compiled a list of diseases making national headlines these days and asked the Vashon Medical Reserve Corps to help us provide an update on their status in our region. Other ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...